The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Lymphoma highlights at ASH 2020
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, discusses some of the highlights in the lymphoma field from ASH 2020. This includes promising efficacy results from a range of bispecific antibodies in aggressive histology lymphoma and trials of novel agents in indolent lymphoma, including CAR T-cell therapies and tyrosine kinase inhibitors. Presentations in Hodgkin lymphoma on camidanlumab tesirine (Cami) and pembrolizumab plus gemcitabine, vinorelbine, and doxorubicin show encouraging results and are worth looking out for. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
